Table 1 Basic characteristics of patients (n = 26)
Characteristics | No. of patients | % |
|---|---|---|
Age (years) (Medium \({\boldsymbol{\pm }}\) SD) | 72.7\(\pm\)10.6 | |
≤65 | 6 | 23.1 |
>65 | 20 | 76.9 |
Sex | ||
Male | 13 | 50.0 |
Female | 13 | 50.0 |
Performance score | ||
0–1 | 16 | 61.5 |
2–4 | 10 | 38.5 |
De novo ATC | ||
Yes | 18 | 69.2 |
No | 8 | 30.8 |
Stage | ||
IVA | 2 | 7.7 |
IVB | 9 | 34.6 |
IVC | 15 | 57.7 |
Metastatic site | ||
Lung | 13 | 50.0 |
Bone | 3 | 11.5 |
Brain | 2 | 7.7 |
Operation | ||
Curative | 9 | 34.6 |
Palliative | 5 | 19.2 |
Radiotherapy | 15 | 57.7 |
Systemic treatment | ||
Chemotherapy | 9 | 34.6 |
Pembrolizumab | 5 | 19.2 |
Sorafenib | 3 | 11.5 |
Lenvatinib | 6 | 23.1 |
Dabrafenib + Trametinib | 9 | 34.6 |
